Navigation Links
TorreyPines Cancels Special Meeting of Stockholders in Order to Pursue Merger Transaction
Date:7/30/2009

ive items related to the merger as to be set forth in the S-4. Such statements are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31, 2008 and TorreyPines' other SEC reports. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and TorreyPines undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

    Company contact:
    Paul Schneider
    TorreyPines Therapeutics, Inc.
    858-623-5665 X125


'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. TorreyPines Therapeutics Reports Third Quarter 2007 Results
7. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
8. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
9. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
10. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
11. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2015 Research and Markets ( ... Jain PharmaBiotech,s new report "Nanobiotechnology Applications, ... An increasing use of ... is anticipated. Nanotechnology will be applied at ... formulations for optimal delivery to diagnostic applications ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... treated and managed with the use of special anti-vascular endothelial growth factor agents ... many more patients, currently does not have a scientific protocol for the many ...
(Date:9/2/2015)... September 2, 2015 Biovista Inc. ... of the 2015 BeHEARD science challenge, a global competition ... disease researchers, access to the latest life science innovations ... repositioning and pathway analytics capability to support Steven ... in the study of Niemann-Pick Disease Type A (NPA), ...
(Date:9/2/2015)... , Sept. 2, 2015 Aytu BioScience, ... developing treatments for urological and related conditions, announced today ... planned private placement convertible note financing, raising a total ... tranches totaling $3.175 million. Josh ... from this private placement are intended to be used ...
Breaking Biology Technology:Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 2Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 3StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3
... Middleton-based Bone Care International Inc. announced on Wednesday that ... , ,Genzyme and Bone Care have signed a definitive agreement ... all-cash transaction valued at $33.00 per fully diluted ... Bone Care's shareholders at a meeting on June 30, and ...
... Perhaps its time to declare 2005 as the Year ... would say its past time. , ,At last ... headline speakers were successful women with words of advice ... included Kay Koplovitz, a South Milwaukee native who launched ...
... today announced that three Wisconsin businesses will receive funding ... Technology Matching Grant (TMG) and Technology Venture Fund (TVF) ... Technologies, Inc., and Bell Brook Labs, LLC, Meanwhile ... merger. , ,Original air date: Saturday, June 18, 2005 ...
Cached Biology Technology:Women entrepreneurs are finding ways to succeed in Wisconsin and beyond 2Women entrepreneurs are finding ways to succeed in Wisconsin and beyond 3
(Date:8/12/2015)... , Aug. 12, 2015   MedNet Solutions , ... entire spectrum of clinical research, is proud to announce ... company,s comprehensive SaaS-based eClinical technology platform, has led the ... first two quarters of 2015.   Q2 2015 and ... quarters measured by contract value sold in the company,s ...
(Date:8/12/2015)... Calif. , Aug. 12, 2015  Synaptics ... of human interface solutions, today announced that four ... announced Match-in-Sensor solution, have officially been named FIDO ... As part of the certification, Synaptics, Natural ID™ ... 1.0 Universal Authentication Framework (UAF) standard and are ...
(Date:8/10/2015)... The latest 364 page report from business intelligence provider ... border security market . Visiongain assesses that this ... Now: Border security is hard to achieve and harder to ... you need to know about - and more importantly, you ... this will impact your company and the border security industry ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 4Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 5Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 7Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 8Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 9
... Center faculty have been elected to the Institute of Medicine ... Election to the Institute of Medicine (IOM) is one of ... and Columbia now has 49 members in this esteemed organization. ... Carolyn Westhoff were among the 65 new IOM members ...
... of the three most frequent malignancies in Western ... patients with early stage and local CRC approaches ... recurrence and the development of distant metastases that ... cause of CRC-related mortality. Although IL-8 ...
... publishers, has entered a publishing partnership with the Estuarine ... Appearing six times a year, the journal plays ... of estuarine and coastal ecosystems. The first issue ... partnership will be officially announced at the ERF 2007 ...
Cached Biology News:3 Columbia University Medical Center faculty elected to Institute of Medicine 2Interleukin-8, key marker for colorectal cancer treatment 2Estuarine Research Federation chooses Springer as publishing partner 2
Glutamate Receptor 5/1a...
Dual Color Mouse anti-Human Anti-Kappa FITC/CD19 PE Class: Antibody Product Group: Immunogluobulin...
... monoclonal [EP282Y] to Asparagine synthetase ... tested applications). ... to residues in the C-terminus ... Entrez GeneID: ...
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 50 ug...
Biology Products: